NTU Researchers Develop Novel Nanodrug Delivery System for High-Grade Brain Cancers

A groundbreaking advancement in the fight against aggressive brain cancers has emerged from National Taiwan University, offering a beacon of hope for patients and medical professionals alike. Researchers, led by Associate Professor Huang Feng-ting of the Department of Biochemical Science and Technology, have engineered a novel nanodrug delivery system that tackles one of the most significant hurdles in brain tumor treatment: the blood-brain barrier. This innovative approach utilizes modified "ferritin nanocages," natural human proteins known for their biocompatibility, to enhance drug delivery directly to tumor sites. The team's meticulous "structure-guided design," employing AI and molecular simulation, has significantly boosted the drug encapsulation efficiency, achieving an eightfold increase compared to previous methods. This breakthrough is particularly crucial for treating glioblastoma, a highly invasive brain cancer with a high recurrence rate and notoriously difficult treatment protocols. By successfully targeting the tumor and inhibiting its growth in animal models, while simultaneously minimizing systemic side effects, this research paves the way for more effective and precise cancer therapies. The findings, published in the "International Journal of Biological Macromolecules," underscore Taiwan's growing prowess in biotechnology and medical research, positioning the nation at the forefront of developing next-generation cancer treatments.

“

This research demonstrates that precise protein engineering design can enhance the efficiency of nanodrug carriers, with potential applications in more cancers and precision medicine in the future.